Cagrilintide research: what the human trial shows

Cagrilintide is a long-acting analogue of amylin, the pancreatic hormone that signals fullness, and it has been through a large randomized phase 2 trial. Here is what that trial found.

Findings

  • A phase 2 trial randomized 706 participants across 57 sites in ten countries, with 26 weeks of treatment and 6 weeks of follow-up.
  • Mean weight reduction ranged from 6.0 per cent at the lowest dose to 10.8 per cent at the highest, against 3.0 per cent on placebo (p<0.001).
  • At the top dose that was 11.5 kg lost, against 3.3 kg on placebo.
  • The top dose also beat the active comparator in the same trial (10.8 per cent against 9.0 per cent, p=0.03).
  • Discontinuation was similar across all groups at about 10 per cent, and the most frequent adverse events were gastrointestinal.

The phase 2 dose-finding trial (Lancet, 2021)

This was a multicentre, randomized, double-blind trial with both placebo and active control, run at hospitals, specialist clinics and primary care centres in Canada, Denmark, Finland, Ireland, Japan, Poland, Serbia, South Africa, the United Kingdom and the United States. Adults without diabetes who had a body mass index of at least 30, or at least 27 with high blood pressure or abnormal blood lipids, were assigned six-to-one to weekly self-injected cagrilintide at one of five doses, to a once-daily active comparator, or to volume-matched placebo. Treatment ran 26 weeks including up to 6 weeks of dose escalation, then 6 weeks of follow-up with no treatment.

What the numbers were

Of 706 participants assigned to cagrilintide, 100 to 102 went into each dose group, with 99 on the active comparator and 101 on placebo. Mean percentage weight reduction from baseline was greater at every cagrilintide dose than placebo: 6.0 to 10.8 per cent, which is 6.4 to 11.5 kg, against 3.0 per cent or 3.3 kg on placebo, giving treatment differences of 3.0 to 7.8 percentage points (p<0.001). The 4.5 mg dose also produced more weight reduction than the once-daily active comparator at its approved dose (10.8 per cent or 11.5 kg, against 9.0 per cent or 9.6 kg, p=0.03). The same pattern held whether the analysis assumed full adherence or counted everyone regardless of adherence.

Tolerability

Seventy-three participants, about 10 per cent, stopped treatment permanently, spread similarly across the groups, mostly because of adverse events, which accounted for 30 people or 4 per cent of the total. Twenty-nine people, 4 per cent, withdrew from the trial. The most frequent adverse events were gastrointestinal, including nausea, constipation and diarrhoea, along with reactions at the injection site, and these were more common on cagrilintide than on placebo. The authors concluded that cagrilintide led to significant reductions in bodyweight and was well tolerated.

What cagrilintide is

Amylin is released by the pancreas with insulin after a meal and signals satiety, but the natural hormone is cleared within minutes and clumps together in solution, which is why it was difficult to study. Cagrilintide is an engineered analogue with those problems solved: it stays in circulation long enough for weekly dosing and remains soluble. It acts at the amylin and calcitonin receptors, a different mechanism from the incretin peptides studied in the same field, which is why it has been examined both on its own and alongside them. Our cagrilintide reconstitution guide covers handling of the research material.

Vistara Labs stocks Cagrilintide research vials, shipped from within Canada to every province.

Frequently asked questions

Has cagrilintide been tested in humans?

Yes. A phase 2 trial randomized 706 participants across 57 sites in ten countries, with a 26-week treatment period and a 6-week follow-up, and reported in The Lancet in 2021.

How much weight did participants lose in the trial?

Mean weight reduction at 26 weeks ranged from 6.0 per cent at the lowest dose to 10.8 per cent at the highest, against 3.0 per cent on placebo (p<0.001). At the top dose that was 11.5 kg against 3.3 kg on placebo.

What is cagrilintide?

Cagrilintide is a long-acting analogue of amylin, a hormone released by the pancreas alongside insulin that signals fullness. It is designed for weekly dosing, where natural amylin lasts only minutes.

Sources: Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398:2160-2172. PMID 34798060. Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397:1736-1748. PMID 33894838.

All products supplied by Vistara Labs are intended for laboratory research use only. They are not drugs, are not approved for human or veterinary use, and are not intended to diagnose, treat, cure or prevent any condition. Nothing on this page constitutes medical advice or guidance for use in humans.

Similar Posts